2 résultats
Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301)
Auteurs / Authors
Des Guetz G, Landre T, Westeel V, Milleron B, Vaylet F, Urban T, Barlesi F, Souquet PJ, Debieuvre D, Braun D, Fraboulet G, Monnet I, Uzzan B, Molinier O, Morin F, Moro-Sibilot D, Morère JF
Journal / Conference
Journal of Geriatric Oncology
Année / Year
2015
PMID / session
Etude IFCT
Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study)
Auteurs / Authors
Morère JF, Bréchot JM, Westeel V, Gounant V, Lebeau B, Vaylet F, Barlési F, Urban T, Souquet PJ, Debieuvre D, Baudrin L, Zalcman G, Morin F, Milleron B, Moro-Sibilot
Journal / Conference
Lung Cancer
Année / Year
2010
PMID / session
Etude IFCT